<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2409">
  <stage>Registered</stage>
  <submitdate>24/06/2009</submitdate>
  <approvaldate>24/06/2009</approvaldate>
  <nctid>NCT00928317</nctid>
  <trial_identification>
    <studytitle>Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate</studytitle>
    <scientifictitle>Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ART621-221</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ART621
Treatment: drugs - ART621
Treatment: drugs - ART621
Treatment: drugs - Placebo

Experimental: ART621 A - ART621 0.75mg/kg per week

Experimental: ART621 B - ART621 1.5 mg/kg per week

Experimental: ART621 C - ART621 3.0mg/kg per week

Placebo Comparator: Placebo arm - 


Treatment: drugs: ART621
3.0mg/kg s.c.

Treatment: drugs: ART621
1.5mg/kg s.c.

Treatment: drugs: ART621
0.75mg/kg s.c.

Treatment: drugs: Placebo
Placebo s.c.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy of ART621 on the signs and symptoms of moderate to severe RA in subjects concomitantly taking methotrexate as assessed by the proportion of subjects achieving an ACR20 response.</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dose-response relationship of ART621 against the signs and symptoms of moderate to severe RA as assessed by additional efficacy, safety and QoL parameters.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity profile of ART621 as assessed by development of HAHAs.</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration versus time profile and population PK of ART621 in subjects with RA.</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of ART621 on immunological parameters and other disease biomarkers.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of a valid written informed consent.

          -  Male or female subjects = 18 and = 80 years old.

          -  Women of childbearing potential, or men of fathering potential, must be using adequate
             (in the investigator's opinion) birth control measures (e.g. abstinence, oral
             contraceptives, intrauterine device, barrier method with spermicide, or surgical
             sterilisation) during the study. Female subjects of childbearing potential must test
             negative for pregnancy prior to enrolling in the study. Post menopausal (cessation of
             menses for more than 2 years) women are eligible for this study.

          -  Diagnosis of RA according to the revised (1987) American College of Rheumatology
             criteria for at least 6 months and no longer than 3 years prior to screening.

          -  Meet ACR functional class criteria I, II or III.

          -  Have active RA at the time of screening and at baseline, defined as = 6 swollen joints
             and = 6 tender joints (from 68 joint count) together with at least 2 of the following
             3 criteria:

               -  CRP level = 1.5 mg/dl;

               -  ESR by Westergren method = 28 mm in the first hour; or

               -  morning stiffness = 45 minutes.

          -  At least one of the following should be present at screening:

               -  documented history or current presence of positive rheumatoid factor;

               -  presence of serum anti-CCP antibodies; or

               -  screening radiographic erosion

          -  Have been tolerating concomitant methotrexate (oral or subcutaneous) for at least 3
             months prior to screening and on a stable dose between 10-25 mg per week for at least
             6 weeks prior to the first study dose. The route of administration must also be
             stable. Use of methotrexate dose of 25-50 mg every 2 weeks is also acceptable. (Other
             DMARDs taken concomitantly with methotrexate are not allowed. Those subjects
             concomitantly receiving additional DMARDs with methotrexate may enter the study by
             stopping the additional DMARD at least 4 weeks prior to first study dose).

          -  If using the following medication, the subject must be on a stable dose for the 4
             weeks prior to the first study dose and maintain that dose throughout the study:

               -  oral corticosteroids, equivalent to = 10 mg of prednisone/day.

               -  one nonsteroidal anti-inflammatory drug (NSAID).

               -  3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates
                  (see Section 7.1 for acceptable doses).

          -  Does not have active or latent TB according to eligibility assessment and screening
             rules (see Section 8.3.1).

          -  Is willing and able to comply with study visits and other protocol requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant, nursing, or planning a pregnancy (both men and women) within 9 months of
             enrolment.

          -  Subjects weighing &gt; 100 kgs.

          -  Screening laboratory tests:

               -  hemoglobin = 8.0 gm/dl

               -  white blood cells = 3.0 x103 cells/µl

               -  neutrophils = 1.5 x 103 cells/µl

               -  platelets =100 x 103 cells/µl

               -  serum transaminase level (AST and ALT) = 2 times upper limit of normal (ULN)

               -  serum creatinine = 0.15 mmol/l

          -  Subjects with diagnosis of juvenile arthritis or other inflammatory or autoimmune
             diseases that might confound the evaluations of benefit from ART621 such as ankylosing
             spondylitis, systemic lupus erythematosus and Lyme disease.

          -  Subjects who have previously failed to respond to any oral or injectable anti-TNFa
             therapy or subjects who have had to stop anti-TNFa therapy for safety reasons.
             Subjects who have successfully responded to anti-TNFa therapy in the past (but
             discontinued for reasons other than safety or lack of efficacy) &gt; 6 months prior to
             study day one may enrol. Patients who have participated in a previous anti-TNFa
             therapy study are eligible if they are confirmed to have received placebo.

          -  Subjects who have previously received the following anti-rheumatic drugs:
             interleukin-1 receptor antagonist [anakinra], rituximab, anti-CD4 antibody, abatacept,
             thalidomide, p38 MAP kinase inhibitor and other agents (other than those listed in
             Section 7.3).

          -  Subjects who have undergone plasmapheresis within 6 months prior to randomisation.

          -  Have received intraarticular, intramuscular, or intravenous corticosteroids, including
             intramuscular adrenocorticotropic hormone, during the 4 weeks prior to the first study
             dose, or non-stable doses of oral steroids.

          -  Subjects with a history of any clinically significant adverse reaction to murine or
             chimeric proteins, including serious allergic reactions.

          -  Subjects with Felty's syndrome or a history of Felty's syndrome.

          -  Subjects who have received or are expecting to receive any live virus or bacterial
             vaccinations within 1 month before first study dose, during the study, or up to 3
             months after the study dose.

          -  Subjects with a history of, presence of, or at high risk of serious infection
             including:

               -  history of active TB, or positive Mantoux test or QuantiFERON Gold test or chest
                  x-ray suggestive of active or healed TB or positive contact history with a
                  subject with active TB within the past 3 months. If subjects have a positive
                  Mantoux test but a negative QuantiFERON Gold test, they may be enrolled.

               -  a serious infection during the 3 months prior study entry (hospitalised or
                  received IV antibiotics for an infection).

               -  chronic or recurrent infectious disease.

               -  systemic fungal infections

               -  opportunistic infection within 3 months prior to screening (refer to 1993 CDC
                  Classification System for HIV Infection).

               -  subjects known, or suspected, to be infected with HIV, hepatitis B, or hepatitis
                  C.

               -  subjects with planned joint replacement surgery or a history of infected joint
                  prosthesis or who have received antibiotics for a suspected infection of a joint
                  prosthesis if that prosthesis has not been removed or replaced.

          -  Subjects with a known history of demyelinating diseases such as multiple sclerosis or
             optic neuritis.

          -  Subjects with evidence of severe, progressive, or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric,
             or cerebral disease.

          -  Concurrent CHF, including medically controlled, asymptomatic CHF or ECG findings
             suggestive of CHF.

          -  Subjects receiving cytotoxic drugs including cyclophosphamide, cyclosporine, or
             alkylating agents within 6 months prior to first study dose.

          -  Known history or evidence of malignancy, lymphoproliferative or neoplastic disease
             with the exception of successfully treated basal or squamous cell carcinoma of the
             skin or cervical intraepithelial neoplasia.

          -  Subjects who have undergone organ transplant (with exception of a corneal transplant
             more than 3 months prior to screening).

          -  Subjects previously enrolled in this study, currently participating in another
             investigational study or treated with any investigational drug within the previous 3
             months or within 5 half-lives, whichever is greater, prior to first study dose.

          -  Any other clinically significant disease or disorder or factors such as substance
             abuse which in the opinion of the investigator make the subject ineligible for
             participation in this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>13</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Georgetown Arthritis Centre - Sydney</hospital>
    <hospital>Coast Joint Care - Maroochydore</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>2298 - Sydney</postcode>
    <postcode>4558 - Maroochydore</postcode>
    <postcode>5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>BUE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Bue</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>CRD</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>SFE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>SJN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>TUC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Calle French</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>San Miguel de Tucuman</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Bruntal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Jihlava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen - Bory</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andh Prad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mahara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamilnadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Prad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kedah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Perak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sarawak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Dzialdowo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arana Therapeutics Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this clinical trial is to assess the safety, efficacy, tolerability,
      immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid
      arthritis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00928317</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>